🚨Trade Alert 🚨 PPCB

This may be the #1 oncology biotech company to watch closely in 2024 and beyond. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ Greetings All, The oncology sector is home to some pretty big pharma beasts that include Amgen and Novartis. This arena got a big boost at the end of last month when Wall Street learned that AbbVie would be buying cancer drug developer Immunogen for a whopping $10 billion. While shares of ImmunoGen rallied 83% on the day of the announcement, other biotech companies also jumped on the news. The scramble to treat and potentially cure cancer has been on for decades and there is BIG money in this space. Cancer is devastating and solving it is lucrative. All this brings attention to a little-known company in the small-cap OTC market that has the potential to transform cancer treatment! Trading at SUB-PENNY prices, Propanc Biopharma, Inc. (OTC: PPCB) has a unique approach to treating metastatic cancer that could turn it into the next Biotech Darling! With executive leadership that has significant scientific, clinical, and operational experience, as well as a novel technology that has large-scale global potential, PPCB is an underfollowed oncology company that should be high on your radar! Who is PPCB? Propanc Biopharma is a clinical-stage biopharmaceutical company developing new cancer treatments for solid tumors. The company has developed a formulation of anti-cancer compounds designed to control or prevent tumors from recurring and spreading throughout the body by using proenzymes, which are inactive enzyme precursors. Enzyme therapy allows us to fight cancer, using natural elements already found within our organism. Enzymes are natural proteins that stimulate and accelerate biological reactions in the body. The enzymes that are secreted by the exocrine pancreas are essential for the digestion of proteins and fats. More than one hundred years ago, Professor John Beard first proposed that pancreatic enzymes represent the body’s primary defense against cancer and would be useful as a cancer treatment. Since then, several scientists have endorsed Beard´s hypothesis with encouraging data from patient treatment. PPCB intends to target patients with limited therapeutic options for the treatment of solid tumors, initially pancreatic, ovarian, or colorectal tumors. A Novel Therapy: PPCB’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer! To view the Company’s "Mechanism of Action" video on its anti-cancer lead product candidate, PRP, click here: [( Lead Candidate PRP: PRP controls cancer cell migration, inhibits tumor blood vessel formation, and triggers the cell’s death. Metastasis occurs because a program inside the cell called the Epithelial-Mesenchymal Transition (EMT) is activated, which causes epithelial cancer cells to become invasive and stem cell-like, allowing these cancer cells to spread and metastasize. The company’s lead product, PRP, is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from the bovine pancreas, administered by intravenous injection. - Mixture of 2 proenzymes from bovine pancreas. - Synergistic ratio of 1:6 inhibits growth of most tumor cells, in vitro. - Examples include ovarian and colorectal cancers. - Efficacy also shown in pancreatic, kidney, breast, brain, prostate, lung, liver, uterine and skin cancers. - Achieved Orphan Drug Designation from the FDA for treating pancreatic cancer. Significant Market Opportunity for Cancer Therapy: 80% of all cancers are solid tumors and PPCB is initially targeting: - Pancreatic cancer – one of the hardest cancers to detect early - Ovarian cancer - the sixth most common cancer in the world - Colorectal tumors – a cancer that is quickly affecting younger people Big News: Last month PPCB announced that PRP enhances the sensitivity of resistant pancreatic tumor cells to standard chemotherapy treatment and alters the tumor microenvironment by decreasing the fibrotic tissue and its malignancy (ability to spread into surrounding tissues). The results were reported by the Company’s joint researcher, Mrs. Belén Toledo Cutillas, MSc, at the laboratory of Professor Macarena Perán, PhD, University of Jaén, Granada, Spain. Dr Julian Kenyon, MD, MB, ChB, Propanc’s Chief Scientific Officer said, "Results from the experiments conducted by Belen demonstrate the effects of PRP on reducing chemoresistance in pancreatic tumor cells, which is a significant issue among pancreatic adenocarcinoma (PDAC) patients, who have a poor 5-year survival rate of less than eight percent.” This could be a game-changer for pancreas cancer patients! First-In-Human Study: PPCB will target the Peter Mac Cancer Center in Melbourne, Australia, as the site for the First-In-Human (FIH) study for PRP in patients with advaAnced solid tumors. Initial discussion held previously with the Clinical Investigator confirmed the remaining development activities to be conducted by the Company prior to filing the clinical trial application for the FIH study. This includes the finished drug product manufacture and validation of the bioanalytical method to analyze the pharmacokinetics (movement of drug within the body) of PRP during the study. More Company Highlights: - 15 years of scientific research and clinical experience suggest PRP has the potential to convert cancerous cells back into normal cells. - Strong pipeline with more than 60 products in clinical development. - Maintains research partnerships with the University of Bath, University of Jaén, University of Granada, and the Foundation for Biosanitary Research of Andalusia Orients. The Bottom Line: Propanc Biopharma, Inc. (OTC: PPCB) could emerge as the next winner in the oncology space and is trading at under a penny currently! The company is developing its lead product, PRP, to treat early-stage cancer and pre-cancerous diseases and as a preventative measure for patients at risk of developing cancer, based on genetic screening. Why does the company stand out? Because there is NO effective standard treatments existing for solid tumors. Tumor cells return to the normal pathways of a differentiated cell. This gives the company a remarkable opportunity to capture a significant market. And remember, PPCB has already achieved Orphan Drug Designation from the FDA for treating pancreatic cancer. "Despite facing significant global challenges in recent years as a micro-cap company, we face the future heading into the new financial year with growing optimism. We expect to enter clinical development stage with PRP, which management believes will identify a new therapeutic approach to the treatment and prevention of metastatic cancer, which remains the main cause of patient death for sufferers. PRP does not exhibit the same severe or even serious side effects compared to standard.” – CEO James Nathanielsz PPCB’s groundbreaking science could mean an exciting 2024 so keep your eyes on the company! Copyright 2023 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in PPCB. We have been currently compensated up to Ten Thousand Dollars Cash ($10,000) via bank wire transfer from a third-party Interactive Offers, LLC for a 1 Day Marketing Program regarding PPCB with a start date of 12/13/2023. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Small Caps Daily 1334 Northampton St Easton, PA 18042 © 2023 | All rights reserved. [Unsubscribe](. [Twitter] [Facebook] [Instagram]